Abstract 586P
Background
Although ctDNA is associated with MRD and recurrence in curatively treated CRC, implementation in clinical practice remains to be optimised. We evaluated the utility of a tumour naive ctDNA assay using serial prospectively collected plasma samples from the ASpirin for Dukes C and high risk Dukes B COLorecTal cancer trial (ASCOLT, NCT00565708), a large randomised phase III study of adjuvant aspirin.
Methods
Plasma samples were collected at baseline, 6 and 12 m in the Australian/ New Zealand cohort (n= 452). In a cohort of 118 pts matched by follow-up time (59 with recurrence [cases] and 59 non-recurrent [controls]), we used an ultra-sensitive ctDNA assay (SafeSEQ, Sysmex Inostics) for MRD detection. Cell pellets were analysed for mutations related to clonal haematopoiesis of indeterminate potential (CHIP). Results were correlated with recurrence and CEA.
Results
291 plasma samples (median 4.0 mL, median DNA 71.0 gen equiv/uL) were analysed (54/118 F; median age 68; 48 high risk stage II, 70 stage III; all had adjuvant chemotherapy; median follow-up 53.1 m). 59 pts recurred at median 12.4 m, of whom 32 had detectable ctDNA (sens 54%, Table). CEA sensitivity for detecting recurrence was 26%. Of the 27 pts with recurrence but no detectable ctDNA, 13 (48%) recurred >12 m after final sample collection. 8 pts without recorded recurrence had plasma mutations (CHIP analysis not available n = 3, all TP53). In multivariate analysis adjusting for known risk factors, ctDNA positivity was independently associated with recurrence (OR, 6.5; 95% CI, 2.2 – 18.9; p<0.001). Median time from 1st positive ctDNA to imaging detected recurrence was 7.9 m (range 0.2 – 40.2). ctDNA change over time and correlation with tumour sequencing will be presented. Table: 586P
Summary of ctDNA Data
Recurrence | No recurrence | Total | |
Positive ctDNA* at any time point | 32 | 8 | 40 |
Negative ctDNA | 27 | 51 | 78 |
Total | 59 | 59 | |
Sensitivity 54% | Specificity 86% |
*SafeSEQ 14 gene CRC MRD assay: AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, KRAS, NRAS, PIK3CA, POLE, PPP2R1A, RNF43, SMAD4 and TP53
Conclusions
Tumour naïve, serial ctDNA detection within 1 year of adjuvant chemotherapy is independently associated with recurrence, noting limitations in sensitivity and specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Australasian Gastro-Intestinal Cancer Trials Group and Royal Australasian College of Physicians Foundation.
Disclosure
A. Starus: Non-Financial Interests, Institutional, Member, Anna Starus is an employee of Sysmex Inostics, Inc: Sysmex Inostics. F.S. Jones: Non-Financial Interests, Institutional, Member, Frederick Jones is an employee of Sysmex Inostics, Inc.: Sysmex Inostics. All other authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10